For example, patients with eye disorders had 3.95 (OR: 3.95 [3.61, 4.33], p < 0.0001) times higher odds of developing neurologic adverse events following PD‐1 inhibitor treatment compared to those without eye disorders. Here, PDCD1 is linked to eye disorder.